Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of 5-FU, Irinotecan, Bevacizumab and Hydroxychloroquine in Drug-Tolerant Persister (DTP)-Selected Patients With Metastatic Colorectal Cancer

NCT05843188 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT05843188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05843188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of 5-FU, Irinotecan, Bevacizumab and Hydroxychloroquine in Drug-Tolerant Persister (DTP)-Selected Patients With Metastatic Colorectal Cancer
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 9, 2023
Completion date
December 24, 2026
Enrollment
155 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer